ArticleAmerican journal of nuclear medicine and molecular imaging2020
[
Article in American journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 32 citations in OpenAlex.
- A tissue-informed deep learning-based method for positron range correction in preclinical [Formula: see text]Ga PET imaging.EJNMMI physics · 2026Article
- Investigating the Theranostic Potential of Elementally Matched [Molecular pharmaceutics · 2026Article
- The clinical utility of total-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.Drugs in context · 2026Review
- A hybrid innovation method based on quality by design and agile scrum paradigms for the development of medicinal products.Scientific reports · 2025Article
- Review
- Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [European journal of nuclear medicine and molecular imaging · 2025Article
- Role of Positron Emission Tomography (PET) in the Diagnosis of Musculoskeletal Disorders.Journal of clinical medicine · 2025Review
- Bidirectional dynamic frame prediction network for total-body [EJNMMI physics · 2024Article
- Evaluation ofAnnals of nuclear medicine · 2024Article
- DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target.Chemical science · 2024Article
- Article
- Comparison of tracer kinetic models forEJNMMI research · 2024Article
- Comparison of Tracer Kinetic Models for 68Ga-PSMA-11 PET in Intermediate Risk Primary Prostate Cancer Patients.Research square · 2023Article
- Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Eligibility forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2022Review
- Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma.Cancers · 2022Review
- Theragnostic Radionuclide Pairs for Prostate Cancer Management:Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [
Indexed as
Identifiers
33329937PMC7724278W3116762035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.